In vivo confocal fluorescence imaging of the intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6.

We present an in vivo fluorescence microscopic evaluation of intratumor distribution of the photosensitizer mono-L-aspartylchlorin-e6 (NPe6) in an intradermal mouse EMT6 tumor model. Although the identification of favorable photophysical and pharmacological properties has led to the development of new photosensitizers in photodynamic therapy, their intratumor distribution kinetics have remained relatively understudied. In this study, we used confocal fluorescence microscopy to follow the transport of NPe6 in vivo after systemic administration through the tail vein. Labeling of vasculature using fluorophore-conjugated anti-CD31 antibodies allows visualization of the uptake of NPe6 in tumor and normal vessels and its partitioning kinetics into the adjacent parenchyma for 3 hours after injection. During the initial 60 minutes after injection, the drug is predominantly confined to the vasculature. Subsequently, it significantly redistributes throughout the extravascular regions with no discernable difference in its extravasation rate between tumor and normal tissues. Further, we investigate the sensitizer's altered intratumor distribution in response to photodynamic therapy irradiation and observe that treatment-induced changes in vessel permeability caused enhanced accumulation of NPe6 in the extravascular space. Our findings are of immediate clinical relevance and demonstrate the importance of an in vivo imaging approach to examine the dynamic process of intratumor drug distribution.

[1]  Jarod C Finlay,et al.  Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. , 2005, Journal of photochemistry and photobiology. B, Biology.

[2]  Barbara W. Henderson,et al.  Choice of Oxygen-Conserving Treatment Regimen Determines the Inflammatory Response and Outcome of Photodynamic Therapy of Tumors , 2004, Cancer Research.

[3]  J. Usuda,et al.  Photodynamic therapy (PDT) for lung cancers. , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Tayyaba Hasan,et al.  Tumor Vascular Permeabilization by Vascular-Targeting Photosensitization: Effects, Mechanism, and Therapeutic Implications , 2006, Clinical Cancer Research.

[5]  Thomas H Foster,et al.  Photophysical Parameters, Photosensitizer Retention and Tissue Optical Properties Completely Account for the Higher Photodynamic Efficacy of meso-Tetra-Hydroxyphenyl-Chlorin vs Photofrin¶ , 2005, Photochemistry and photobiology.

[6]  D. Kessel,et al.  Pharmacokinetics of N-aspartyl chlorin e6 in cancer patients. , 1997, Journal of photochemistry and photobiology. B, Biology.

[7]  D. Kessel,et al.  Killing tumor cells: the effect of photodynamic therapy using mono-L-aspartyl chlorine and NS-398. , 2005, American journal of surgery.

[8]  Effects of photodynamic therapy using a fractionated dosing of mono-L-aspartyl chlorin e6 in a murine tumor. , 2005, Journal of photochemistry and photobiology. B, Biology.

[9]  P. H. Moore,et al.  Effects of photodynamic therapy using mono-L-aspartyl chlorin e6 on vessel constriction, vessel leakage, and tumor response. , 1994, Cancer research.

[10]  T. Wieman,et al.  Photodynamic therapy using mono-L-aspartyl chlorin e6 (Npe6) for the treatment of cutaneous disease: a Phase I clinical study. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  Barbara W Henderson,et al.  Photodynamic therapy: a means to enhanced drug delivery to tumors. , 2003, Cancer research.

[12]  D. Kessel Correlation between subcellular localization and photodynamic efficacy , 2004 .

[13]  T. Foster,et al.  Confocal fluorescence spectroscopy and anisotropy imaging system. , 2003, Optics letters.

[14]  M. Trotter,et al.  The use of fluorescent probes to identify regions of transient perfusion in murine tumors. , 1989, International journal of radiation oncology, biology, physics.

[15]  T. Albertson,et al.  Pharmacokinetics and clinical effects of mono‐l‐aspartyl chlorin e6 (NPe6) photodynamic therapy in adult patients with primary or secondary cancer of the skin and mucosal surfaces , 2005, Photodermatology, photoimmunology & photomedicine.

[16]  T. Vogl,et al.  A multicenter Phase I safety study of intratumoral photoactivation of talaporfin sodium in patients with refractory solid tumors , 2003, Cancer.

[17]  M. Biel,et al.  mTHPC‐mediated photodynamic therapy in patients with advanced, incurable head and neck cancer: a multicenter study of 128 patients , 2004, Head & neck.

[18]  Lina Bolotine,et al.  Temporally and Spatially Heterogeneous Distribution of mTHPC in a Murine Tumor Observed by Two-color Confocal Fluorescence Imaging and Spectroscopy in a Whole-mount Model , 2005, Photochemistry and photobiology.

[19]  C J Gomer,et al.  Tissue distribution and photosensitizing properties of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1990, Cancer research.

[20]  P B Cerrito,et al.  The role of microvascular damage in photodynamic therapy: the effect of treatment on vessel constriction, permeability, and leukocyte adhesion. , 1992, Cancer research.

[21]  Michael R Hamblin,et al.  In vivo fluorescence imaging of the transport of charged chlorine6 conjugates in a rat orthotopic prostate tumour , 1999, British Journal of Cancer.

[22]  B. Pogue,et al.  Analysis of Effective Molecular Diffusion Rates for Verteporfin in Subcutaneous Versus Orthotopic Dunning Prostate Tumors¶ , 2004, Photochemistry and photobiology.

[23]  T. Foster,et al.  Photofrin and light induces microtubule depolymerization in cultured human endothelial cells. , 1992, Cancer research.

[24]  R. Jain The next frontier of molecular medicine: Delivery of therapeutics , 1998, Nature Medicine.

[25]  C. Hadjur,et al.  Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval. , 1997, British Journal of Cancer.

[26]  Arjun G. Yodh,et al.  Noninvasive Monitoring of Murine Tumor Blood Flow During and After Photodynamic Therapy Provides Early Assessment of Therapeutic Efficacy , 2005, Clinical Cancer Research.

[27]  C J Gomer,et al.  Metabolic properties and photosensitizing responsiveness of mono-L-aspartyl chlorin e6 in a mouse tumor model. , 1992, Cancer research.

[28]  J. Kennedy,et al.  A recipe for the preparation of a rodent food that eliminates chlorophyll-based tissue fluorescence. , 1995, Journal of photochemistry and photobiology. B, Biology.

[29]  Ken Kang-Hsin Wang,et al.  A comprehensive mathematical model of microscopic dose deposition in photodynamic therapy. , 2006, Medical physics.